Table 5.
Clinical course of the gefitinib-responders who achieved PD, underwent chemotherapy, and rechallenged with gefitinib
| No. | Chemotherapy regimen after failure of gefitinib | Best response of the chemotherapy | Response of gefitinib rechallenge | Time to re-progression (month) |
| 5 | GEM+VNR | PR | PR | 6.2 |
| 6 | GEM+VNR | PD | SD | 7.8 |
| 7 | GEM+DTX | SD | PD | 0.6 |
| 8 | CBDCA+CPT-11 → AMR → S-1 | SD | SD | 1.9+ |
| 9 | DTX | SD | SD | 4.3+ |
| 10 | DTX | SD | NE | 0.9+ |
"Rechallenge" of gefitinib indicates restarting gefitinib after cessation of gefitinib followed by other chemotherapy. GEM, gemcitabine; VNR, vinorelbine; DTX, docetaxel; CBDCA, carboplatin; CPT-11, irinotecan; AMR, amrubicin; Time to re-progression, time to progression from the date of rechallenging gefitinib; +, still continuing the response at the last date of follow-up